Why Kazia Therapeutics is Australia’s biotech shining star

By Marc Sinatra | More Articles by Marc Sinatra

Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corporate Connect Research report was released. Corporate Connect biotech analyst Marc Sinatra updates the market post the ASX announcement by Kazia of further Paxalisib data.

For full details refer to the research report below or click here to download your copy.

Marc Sinatra

About Marc Sinatra

Corporate Connect Research Analyst Marc Sinatra has had a broad career across the life-science industry, having worked in it for over 25 years. Marc spent his time providing specialist consulting services to venture capital companies, listed and unlisted life-science companies, providing company analysis for various uses, and investing in the ASX-listed life-science sector.

View more articles by Marc Sinatra →